{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T05:54:15Z","timestamp":1721973255052},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,12]],"date-time":"2013-08-12T00:00:00Z","timestamp":1376265600000},"content-version":"vor","delay-in-days":834,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/s1413-8670(11)70180-5","type":"journal-article","created":{"date-parts":[[2012,11,2]],"date-time":"2012-11-02T15:34:02Z","timestamp":1351870442000},"page":"225-230","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B"],"prefix":"10.1016","volume":"15","author":[{"given":"Astrid","family":"Wiens","sequence":"first","affiliation":[]},{"given":"Rafael","family":"Venson","sequence":"additional","affiliation":[]},{"given":"Cassyano","family":"Janu\u00e1rio Correr","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/S1413-8670(11)70180-5_bib1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3949\/ccjm.75a.07019","article-title":"Hepatitis B virus infection: understanding its epidemiology, course, and diagnosis","volume":"75","author":"Elgouhari","year":"2008","journal-title":"Cleve Clin J Med."},{"issue":"5","key":"10.1016\/S1413-8670(11)70180-5_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1590\/S1413-86702008000500002","article-title":"Lamivudine for chronic hepatitis B: a brief review","volume":"12","author":"Palumbo","year":"2008","journal-title":"Braz J Infect Dis."},{"issue":"4","key":"10.1016\/S1413-8670(11)70180-5_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3748\/wjg.15.423","article-title":"DNA-guided hepatitis B treatment, viral load is essential, but not sufficient","volume":"15","author":"Barcena Marugan","year":"2009","journal-title":"World J Gastroenterol."},{"issue":"1","key":"10.1016\/S1413-8670(11)70180-5_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1590\/S0037-86822007000100004","article-title":"Long-term use of lamivudine for treating chronic hepatitis B in the State of Mato Grosso","volume":"40","author":"Souto","year":"2007","journal-title":"Rev Soc Bras Med Trop."},{"issue":"12","key":"10.1016\/S1413-8670(11)70180-5_bib5","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2008.08.021","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update","volume":"6","author":"Keeffe","year":"2008","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"10.1016\/S1413-8670(11)70180-5_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/S1413-8670(11)70180-5_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2893.2009.01078.x","article-title":"Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides","volume":"16","author":"Nguyen","year":"2009","journal-title":"J Viral Hepat."},{"key":"10.1016\/S1413-8670(11)70180-5_bib8","unstructured":"Minist\u00e9rio da Sa\u00fade. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para o Tratamento da Hepatite Viral Cr\u00f4nica B e Coinfec\u00e7\u00f5es. In: Secretaria de Vigil\u00e2ncia em Sa\u00fade - Departamento de DST AeHV, editor.: Programa Nacional para a Preven\u00e7\u00e3o e o Controle das Hepatites Virais; 2009. p. 128."},{"issue":"4","key":"10.1016\/S1413-8670(11)70180-5_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1590\/S0037-86822007000400016","article-title":"Advances in the treatment of hepatitis B","volume":"40","author":"Ferreira","year":"2007","journal-title":"Rev Soc Bras Med Trop."},{"issue":"8","key":"10.1016\/S1413-8670(11)70180-5_bib10","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00535-009-0076-0","article-title":"Lamivudine-toentecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance","volume":"44","author":"Kurashige","year":"2009","journal-title":"J Gastroenterol"},{"issue":"4","key":"10.1016\/S1413-8670(11)70180-5_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1590\/S0037-86822000000400010","article-title":"Diagnosis and treatment of hepatitis B","volume":"33","author":"Ferreira","year":"2000","journal-title":"Rev Soc Bras Med Trop."},{"issue":"25","key":"10.1016\/S1413-8670(11)70180-5_bib12","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/S1413-8670(11)70180-5_bib13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/S1413-8670(11)70180-5_bib14","first-page":"73","article-title":"Avalia\u00e7\u00e3o Farmacoecon\u00f4mica instrumento de medida dos benef\u00edcios na aten\u00e7\u00e3o farmac\u00eautica","volume":"22","author":"Mota","year":"2003","journal-title":"Acta Farm Bonaerense"},{"issue":"1","key":"10.1016\/S1413-8670(11)70180-5_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/keg451","article-title":"Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK","volume":"43","author":"Brennan","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/S1413-8670(11)70180-5_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1590\/S0104-42302007000600013","article-title":"Cost estimates of chronic hepatitis B virus for the Brazilian unified health system in 2005","volume":"53","author":"Castelo","year":"2007","journal-title":"Rev Assoc Med Bras."},{"issue":"2","key":"10.1016\/S1413-8670(11)70180-5_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","article-title":"Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial","volume":"47","author":"Hou","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/S1413-8670(11)70180-5_bib18","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"issue":"5 Suppl","key":"10.1016\/S1413-8670(11)70180-5_bib19","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/hep.22884","article-title":"Hepatitis B virus DNA levels and outcomes in chronic hepatitis B","volume":"49","author":"Chen","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/S1413-8670(11)70180-5_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1524-4733.2007.00221.x","article-title":"HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan","volume":"11","author":"Veenstra","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/S1413-8670(11)70180-5_bib21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1477-7525-7-52","article-title":"Health-related quality of life of Southern Chinese with chronic hepatitis B infection","volume":"7","author":"Lam","year":"2009","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"10.1016\/S1413-8670(11)70180-5_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","article-title":"The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons","volume":"11","author":"Levy","year":"2008","journal-title":"Value Health"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867011701805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867011701805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T20:00:30Z","timestamp":1540152030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867011701805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1413867011701805"],"URL":"https:\/\/doi.org\/10.1016\/s1413-8670(11)70180-5","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}